|Bid||7,355.00 x 0|
|Ask||7,351.00 x 0|
|Day's range||7,156.69 - 7,377.00|
|52-week range||109.51 - 8,227.88|
|Beta (3Y monthly)||0.23|
|PE ratio (TTM)||46.02|
|Earnings date||14 Feb 2020|
|Forward dividend & yield||2.19 (3.01%)|
|1y target est||78.83|
Britain's BT has told a company promoting digital skills it would continue working with it if it dropped Prince Andrew as a patron. The British royal has been engulfed in a growing scandal since he gave a TV interview on Saturday to discuss his friendship with Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. Andrew denied an allegation that he had sex with a 17-year-old girl procured for him by Epstein but said he did not regret the friendship.
A scheme for entrepreneurs founded by Prince Andrew has taken down the logos of its corporate sponsors from its website, as firms and charities distance themselves from the British royal over a sex scandal. Andrew, Queen Elizabeth's second son, denies an allegation that he had sex with a 17-year-old girl procured for him by his friend Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. The scandal has escalated since Andrew's rambling denials and explanations in a disastrous TV interview aired on Saturday left many viewers incredulous, and his apparent lack of compassion for Epstein's victims drew widespread condemnation.
Stockopedia’s own data points to a jarringly simple stock market truth amidst the daily whirlwind of financial data: share prices that have gone up tend to kee8230;
European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector. The pan-European STOXX 600 index finished little changed, after having spent most of the session in negative territory. The European automobiles and parts sector dropped 2.1%, its steepest fall in about four weeks, with Germany's Volkswagen leading declines after it slashed its operating profit and sales growth outlook due to slowdown in the auto sector.
UK mid-caps closed at their highest level in nearly 14 months on Monday, boosted by polls pointing to victory by the ruling Conservatives in upcoming elections, while a near 5% drop in insurer Aviva weighed on the main board. The domestically-focused FTSE 250 index rose 0.2% while the FTSE 100 added 0.1%.
London's main bourse retreated on Wednesday as traders grew weary of mixed trade signals from U.S. President Donald Trump, while mid-caps slid on the back of weak economic data and a plunge in Tullow Oil. The more internationally-exposed FTSE 100 fell 0.2%, trimming some early losses as exporter stocks such as Diageo and AstraZeneca benefited from a weaker pound. The jump in exporter shares also helped the bourse outperform the broader European benchmark index.
AstraZeneca said that safety data on roxadustat underpinned the British drugmaker's hopes for the anaemia drug to become a standard treatment for patients with kidney disease. It said pooled data from several late-stage trials showed that roxadustat did not increase the risk of potentially deadly cardiovascular complications like heart attacks and strokes when used instead of epo, which is the standard treatment for dialysis patients against lack of red blood cells from kidney disease. For a subgroup of patients that had just recently gone on dialysis the cardiovascular risk was about one third lower for patients on roxadustat compared with those on epo, it added.
Harvey Jones says these two FTSE 100 (INDEXFTSE:UKX) pharmaceutical stocks could help your portfolio weather a recession.
Top Indian drugmaker Sun Pharmaceutical Industries Ltd said on Wednesday Britain's AstraZeneca would distribute some of Sun's cancer treatment drugs in China, the world's second-largest pharmaceutical market. As per the licensing agreement, Sun will be responsible for development, regulatory filings and manufacturing of the drugs, while AstraZeneca will exclusively promote and distribute the products in China, according to a filing https://www.bseindia.com/xml-data/corpfiling/AttachLive/e10d3bee-3ab1-4a0f-ab45-600f16796260.pdf to Indian stock exchanges.
AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country. The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters. AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said.
When the going gets tough, dividends get cut. Given today's volatile market conditions, mature economic cycle, and historically high dividend yields that are o8230;
As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country's largest venture capital firms where he worked prior to his time in government. Near the top of his list are companies researching new kinds of antibiotics, an issue he advocated for while at the FDA.
A rally in pharmaceutical stocks led by industry giants GlaxoSmithKline and AstraZeneca helped the FTSE 100 outshine most global peers on Wednesday while investors waited for the outcome of the U.S. Federal Reserve's policy meeting. The FTSE 100 reversed early losses to close up 0.3%, with the pharma sub-index scaling an all-time high, up 2.5% after GSK again upgraded its 2019 targets. Moves on both indexes were however subdued with investors waiting for the Fed to announce its policy decision.
The treatment, Seroquel, and another version, Seroquel XR, have lost patent protections in Europe and Russia, AstraZeneca said. The drug variants are primarily used to treat schizophrenia and bipolar disorder. AstraZeneca halted years of falling sales in 2018, marking a turn around after crumbling sales due to patent losses on older drugs, and has been focusing on newer medicines including those for cancer, diabetes and heart conditions.
The exporter-laden FTSE 100 recovered from early losses on Monday despite a rebound in sterling, boosted by gains in leading drug stocks and as prospects for a U.S.-China trade agreement powered miners and industrials. The blue chip index closed 0.1% higher, lagging peers on Wall Street and in Europe as a near 4% drop in HSBC after an underwhelming earnings update, and a slide in dollar earners, capped gains. The more domestically-focused FTSE 250 outperformed with a 0.5% rise ahead of a parliamentary vote on Prime Minister Boris Johnson's demand for a general election.
The AstraZeneca share price jumped over 5% on a trading update last week, but there's a big reason to avoid the stock, argues G A Chester.
The never-ending Brexit saga makes the investing environment very testing for share pickers. I'd take the tension away by buying this brilliant FTSE 100 share for an ISA, says Royston Wild.